首页|靶向人源BCMA的嵌合抗原受体T细胞构建及体外抗肿瘤活性研究

靶向人源BCMA的嵌合抗原受体T细胞构建及体外抗肿瘤活性研究

扫码查看
目的:通过对CAR结构的ScFv单链可变区进行改造,构建并筛选具有更强杀伤肿瘤细胞功能的新型靶向人源B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)-T细胞。方法:构建靶向人源BCMA的CAR分子,用逆转录病毒载体包装成功后转导健康志愿者的T细胞,制备Anti-BCMA-CAR-T细胞。将Anti-BCMA-CAR-T细胞作为观察组,普通T细胞作为对照组,将其与RP-MI-8226细胞共培养,采用CFSE染色的T细胞增殖实验观察两组体外增殖能力。采用荧光素酶化学发光实验检测两组细胞在不同效靶比(1∶8、1∶4、1∶2、1∶1、2∶1、4∶1)对RPMI-8226细胞的杀伤效率,采用流式细胞术检测两组细胞在不同效靶比(1∶4、1∶2、1∶1、2∶1、4∶1)对RPMI-8226细胞的杀伤效率。结果:CFSE检测结果显示,与对照组比较,观察组FITC信号明显左移,表明T细胞增殖能力越强。流式细胞术检测结果显示,相同效靶比时,观察组对RPMI-8226细胞的杀伤效率均高于对照组(P均<0。05);荧光素酶化学发光实验结果显示,相同效靶比时,观察组对RPMI-8226细胞的杀伤效率均高于对照组(P均<0。05)。在效靶比为4∶1时,CAR170-T(未经改造的传统的ScFv)细胞和CAR174-T(经改造的ScFv)细胞的杀伤效率分别达到了 88。5±0。3%和98。5±0。7%。结论:通过对CAR结构的ScFv单链可变区进行改造后成功构建出的新型靶向BCMA的CAR-T细胞,它能保持较强的增殖活性且具有更强的杀伤肿瘤细胞的能力。
Construction of Chimeric Antigen Receptor T Cells Targeting Human BCMA and its Antitumor Activity in Vitro
Objective:To construct and screen the new type of chimeric antigen receptor CAR-T cell targeting human-derived B cell maturation antigen(BCMA),By modifying the ScFv single-chain variable region of the CAR structure,a novel chimeric antigen receptor(CAR)-T cell targeting human B-cell maturation antigen(BCMA)with a stronger ability to kill tumor cells was constructed and screened.Methods:We constructed a CAR molecule targeting BCMA human ScFv,and after successful packaging with retroviral vector,transducing T cells from healthy volunteers to prepare Anti-BCMA-CAR-T cells.Anti-BCMA-CAR-T cells were used as the observation group and normal T cells were used as the control group,they were co-cultured with RPMI-8226 cells,and the proliferation ability of the two groups in vitro was observed by the T cell proliferation experiment stained with CFSE.The killing efficiency of two groups of cells on RPMI-8226 cells at different effect-to-target ratios(1∶8,1∶4,1∶2,1∶1,2∶1,4∶1)was detected by luciferase chemiluminescence assay.Flow cytometry was used to detect the killing efficiency of the two groups of cells on RPMI-8226 cells at different effect-to-target ratios(1∶4,1∶2,1∶1,2∶1,4∶1).Results:CFSE detection results showed that compared with the control group,the FITC signal in the observation group shifted significantly to the left,indicating that the T cell proliferation ability was stronger.The results of flow cytometry showed that at the same effect target ratio,the killing efficiency of the observation group on RPMI-8226 cells was higher than that of the control group(both P<0.05);the results of luciferase chemiluminescence experiment showed that the same effect target ratio,the killing efficiency of RPMI-8226 cells in the observation group was higher than that in the control group(P<0.05).When the effect-to-target ratio was 4∶1,the killing efficiencies of CAR 170-T(unmodified conventional ScFv)cells and CAR174-T(modified ScFv)cells reached 88.5±0.3%and 98.5±0.7%,respectively.Conclusion:We successfully constructed a novel type of BCMA-targeting CAR-T cells by modifying the ScFv single-chain variable region of the CAR structure,which can maintain strong proliferative activity and have a stronger ability to kill tumor cells.

B cell maturation antigenChimeric antigen receptorScFv single-chain variable regionT cell

崔鑫铭、董宇曦、尚凤琴、刘秀盈、朱晶晶、刘静静、冯义超、王建勋

展开 >

北京中医药大学生命科学学院 北京 102400

深圳北京中医药大学研究院 广东深圳 518118

B细胞成熟抗原 嵌合抗原受体 ScFv单链可变区 T细胞

王建勋高层次人才科研启动经费项目

9011451310032

2024

现代生物医学进展
黑龙江省森工总医院 哈尔滨医科大学附属第四医院

现代生物医学进展

CSTPCD
影响因子:0.755
ISSN:1673-6273
年,卷(期):2024.24(1)
  • 27